<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cision Wire</title>
    <link>http://news.cision.com/</link>
    <description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description>
    <pubDate>Sat, 25 May 2013 10:24:00 GMT</pubDate>
    <image>
      <title>Cision Wire</title>
      <width>120</width>
      <height>32</height>
      <link>http://news.cision.com/</link>
      <url>http://news.cision.com/ui/images/CisionLogoSmall.gif</url>
    </image>
    <item>
      <title>XSpray and Cerbios-Pharma announce partnership on the use of XSpray’s RightSize(TM) technology</title>
      <link>http://news.cision.com/xspray-microparticles-ab/r/xspray-and-cerbios-pharma-announce-partnership-on-the-use-of-xspray-s-rightsize-tm--technology,c9298299</link>
      <guid isPermaLink="false">cision1106706</guid>
      <description><![CDATA[<p ><em><strong>Stockholm, Sweden &ndash; September 4, 2012</strong></em><em>. </em><em>XSpray Microparticles AB today announced a partnership with Cerbios-Pharma SA of Lugano, Switzerland for the joint development of HPAI (High Potency Active Ingredients). HPAI development will be provided by XSpray in </em><em>Stockholm, while the cGMP production for clinical and commercial use will be carried out at Cerbios in Lugano.</em></p>]]></description>
      <pubDate>Tue, 04 Sep 2012 10:00:00 GMT</pubDate>
    </item>
  </channel>
</rss>